Peer-reviewed veterinary case report
Ovariohysterectomy during tumor removal in dogs with mammary cancer
By Kristiansen, V M et al.·Published in Journal of veterinary internal medicine·2016·Faculty of Veterinary Medicine and Biosciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of Ovariohysterectomy at the Time of Tumor Removal in Dogs with Mammary Carcinomas: A Randomized Controlled Trial.
- Species:
- dog
Plain-English summary
A group of 60 female dogs with mammary tumors underwent surgery to remove the tumors, with some also having their ovaries and uterus removed at the same time. The study aimed to see if this additional surgery (called ovariohysterectomy) would help improve their chances of recovery. While overall results showed no significant difference in relapse or death rates, certain dogs with specific tumor characteristics, like grade 2 tumors or high estrogen levels, did seem to benefit from the extra surgery. This suggests that for some dogs, removing the ovaries and uterus might help reduce the chance of the cancer coming back.
People also search for: dog mammary tumor treatment · ovariohysterectomy benefits for dogs · dog cancer recurrence prevention
Abstract
BACKGROUND: Ovarian hormones play crucial roles in mammary carcinogenesis. However, whether ovarian ablation by ovariohysterectomy (OHE) improves the prognosis in dogs with mammary carcinomas is unclear. OBJECTIVES: Determine if OHE at the time of mastectomy improves the prognosis in dogs with mammary carcinomas and evaluate if hormonal factors influence the effect of OHE. ANIMALS: Sixty intact dogs with mammary carcinomas. METHODS: Dogs were randomly assigned in a 1:1 ratio to undergo OHE (n = 31) or not (n = 29) at the time of tumor removal. Peri-surgical serum estradiol (E2) and progesterone concentrations were measured, tumor diagnosis was confirmed histologically, and tumor estrogen and progesterone receptor status was immunohistochemically determined. The dogs were monitored for recurrence and metastases every 3-4 months for at least 2 years. Uni- and multivariable survival analyses were performed with relapse and all-cause death as endpoints in addition to univariable subgroup analyses. RESULTS: Overall, OHE did not significantly decrease hazard of relapse (hazard ratio [HR], 0.64; P = .18) or all-cause death (HR, 0.87; P = .64) in univariable analyses. In multivariable analysis OHE did not significantly influence the hazard of relapse (HR, 0.54; P = .12), but an interaction effect was identified between ER status and E2 (P = .037). Subgroup analysis identified decreased hazard of relapse in the OHE group compared to the non-OHE group in the subsets of dogs with increased E2 (HR, 0.22; P = .012) or grade 2 tumors (HR, 0.26; P = .02). CONCLUSION: Dogs with grade 2, ER-positive tumors, or with increased peri-surgical serum E2 concentration represent a subset of dogs with mammary carcinomas likely to benefit from OHE.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26687731/